BVS - Bioventus GAAP EPS of -$0.01 misses by $0.07 revenue of $130.4M in-line; issues FY22 guidance

Bioventus press release (NASDAQ:BVS): Q4 GAAP EPS of -$0.01 misses by $0.07. Revenue of $130.4M (+32.3% Y/Y) in-line. Adjusted EBITDA of $28.5 million, compared to $28.2 million in the prior year. Non-GAAP gross profit was $99.6 million, or 76.3% of net sales, compared to $78.6 million, or 79.7% of net sales, for the fourth quarter of 2020, an increase of $21.0 million, or 26.7%, year over year. Non-GAAP operating margin was 17.1% of net sales, compared to 17.7% of net sales for the fourth quarter of 2020. For the twelve months ending December 31, 2022, the Company expects: Net sales of $545 million to $565 million, representing year over year growth of approximately 26% to 31% vs. consensus of $558.63M; Adjusted EBITDA of $94 million to $107 million, compared to $80.8 million for the year ended December 31, 2021. The company is not providing guidance for adjusted diluted earnings per share due to the

For further details see:

Bioventus GAAP EPS of -$0.01 misses by $0.07, revenue of $130.4M in-line; issues FY22 guidance